STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials Staidson BioPharma Inc., a wholly-owned subsidiary of Staidson (Beijing) Biopharmaceutical Co., Ltd. received a notification from the Food and Drug Administration (FDA) approving the use of STSA-1005 injection for clinical trials in the treatment of severe COVID-19 indications.
STSA-1002 injection gains approval from the U.S. FDA to conduct clinical trials Staidson (Beijing) Biopharmaceutical Co., Ltd. has received approval from the U.S. Food and Drug Administration (FDA), for the use of STSA-1002 injection, and independently developed antagonist of complement receptor signaling for the treatment of COVID-19 indications.
Announcement on obtaining the Phase I clinical study summary report of STSP-0601 for injection Staidson (Beijing) Biopharmaceutical Co., Ltd. obtained a clinical research summary report on the phase I clinical trial of STSP-0601 for injection. STSP-0601 for injection is a coagulation factor X activator for the treatment of bleeding in patients with hemophilia A or B with inhibitors.
